BioArctic AB (publ) (BRCTF)
OTCMKTS
· Delayed Price · Currency is USD
18.35
0.00 (0.00%)
May 16, 2025, 4:00 PM EDT
BioArctic AB Revenue
In the year 2024, BioArctic AB had annual revenue of 257.35M SEK, down -58.22%. BioArctic AB had revenue of 101.24M in the quarter ending December 31, 2024, with 818.24% growth.
Revenue
257.35M SEK
Revenue Growth
-58.22%
P/S Ratio
72.43
Revenue / Employee
2.41M SEK
Employees
107
Market Cap
1.68B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
BioStem Technologies | 332.45M |
BioArctic AB News
- 7 days ago - Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET - PRNewsWire
- 11 days ago - Exidavnemab phase 2a study expanded to include MSA patients - PRNewsWire
- 6 weeks ago - The European Commission refers lecanemab decision to Appeal Committee - PRNewsWire
- 2 months ago - BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference - PRNewsWire
- 2 months ago - BioArctic receives Orphan Drug Designation for exidavnemab the US - PRNewsWire
- 2 months ago - Therapeutic Goods Administration decides not to register lecanemab in Australia - PRNewsWire
- 2 months ago - The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU - PRNewsWire
- 3 months ago - Leqembi® sales reaches €200 million - first sales milestone achieved - PRNewsWire